baber/WOPTO huggingface dataset:
Patent NZ-550985-A (NZ)
Title: Cyclic amide derivatives, and their production and use as antithrombotic agents
Inventor: KUBO KEIJI
IPC: A61K31/45
Filed: 2005-05-20
Abstract: Disclosed is a cyclic amide derivative which inhibits activated blood coagulation factor X (FXa) to exhibit anticoagulant activity and antithrombotic activity. The compound is useful as a drug for treating thrombosis, and is represented by the formula (I): wherein R1 represents a naphthyl which may be substituted with a halogen atom, W represents a bond, a represents 0, 1, or 2, X1 represents a C1-6 alkylene which may be substituted with a hydroxy group, Y1 represents -C(O)-, A represents a piperazine ring or a piperidine ring, and the remaining substituents are as defined in the specification.
Patent NZ-553405-A (NZ)
Title: Nucleoside phosphonate conjugates as anti-HIV agents
Inventor: BOOJAMRA CONSTANTINE G
IPC: A61K31/662
Filed: 2005-07-26
Abstract: Disclosed are phosphorus substituted anti-viral inhibitory compounds of formula (i), compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Patent NZ-553811-A (NZ)
Title: Telemetry using "always-on" communication connection system and method
Inventor: WHITFIELD ANDREW
Filed: 2005-05-12
Abstract: A telemetry system for signalling occurrence of a first event at a first location comprises: an "always on" network and a first sensor communications device communicatively connected to the "always on" network, capable of detecting occurrence of the first event at the first location. The first sensor communications device is capable of directly communicating over the "always on" network. The telemetry system also has a central host communications device located at the host location, capable of communicating over the "always on" network with the first sensor communications device; and a first unique identifier of the first sensor communications device, employed in communicating over the "always on" network with the central host communications device. The central host communications device located at the host location is capable of communicating over the "always on" network directly with the first sensor communications device. The first sensor communications device, on detection of occurrence of the first event. at the first location, indicates the occurrence of the first event by communicating over the "always on" network to the central host communications device. The central host communications device recognises the first sensor communications device in communication over the "always on" network by the first unique identifier of the first sensor communications device.
Patent NZ-563820-A (NZ)
Title: Sugar-coated tablet
Inventor: UCHIYAMA YOSHIHIRO
IPC: A61K9/16
Filed: 2006-06-09
Abstract: Disclosed is a pharmaceutical preparation which comprises a portion containing an active ingredient unstable to oxygen comprised of (R)-5,6-dimethoxy-2-[2,2,4,6,7-pentamethyl-3-(4-methylphenyl)-2,3-dihyro-1-benzofuran-5-yl]isoindoline and a sugar-coated layer containing (1) sugar alcohol comprised of erythritol as a sugar-coating base material and (2) a binder comprised of gum Arabic, wherein the portion is coated with the sugar-coated layer.
Patent NZ-565215-A (NZ)
Title: Granular turf safe 2-[4-methylsulfonyl-2-nitrobenzoyl]-1,3-cyclohexanedione compositions
Inventor: BAKER ROBERT D
IPC: C05G3/60
Filed: 2006-07-18
Abstract: Disclosed is a granular composition comprising mesotrione coated on or impregnated into a granular substrate material in an amount effective to control weeds in a turfgrass, without causing significant injury to the turfgrass when the granular composition is applied to the turfgrass, relative to when a liquid mesotrione composition is applied to the turfgrass. A method for controlling the growth of weeds in a turfgrass without causing significant injury to the turfgrass by applying the above mentioned granular composition is also disclosed.
Patent NZ-566779-A (NZ)
Title: Controlling aeration gas flow and mixed liquor circulation rate using an algorithm
Inventor: ZHA FUFANG
IPC: B01D61/22
Filed: 2006-10-06
Abstract: Disclosed is a method of controlling operating parameters of a membrane bioreactor system. The method includes the steps of: determining a control algorithm, and controlling aeration gas flow and mixed liquor circulation rate operating parameters of the system using the algorithm. The algorithm is based on the relationship between a value of a parameter of an influent provided to the system and an optimal performance measurement parameter of the system.
Patent NZ-568254-A (NZ)
Title: 1,4-Benzodiazepine-2,5-diones for regulating cell death and treating autoimmune diseases
Inventor: GLICK GARY D
IPC: A61K31/55
Filed: 2006-11-01
Abstract: Disclosed is a compound of the pictured formula, where R3 is hydrogen or alkyl and Hal is halogen. The specification also generally discloses further benzodiazepine compounds. Also disclosed is the use of the above compound for treating a hyperproliferative disorder, autoimmune disorder, chronic inflammatory condition, or atherosclerosis, including conditions such as graft-versus-host disease, psoriasis, rheumatoid arthritis, cancer, Sjogren's syndrome, myasthenia gravis, asthma, systemic lupus erythematosus, multiple sclerosis, celiac sprue, idiopathic thrombocytopenia purpura, scleroderma, Crohn's Disease, inflammatory bowel disease, or ulcerative colitis.
Patent NZ-574941-A (NZ)
Title: An electric lock for a door with a power receiver and a power transmitter having parallel magnetic axes when a door is closed
Inventor: LAMBROU HARRY
IPC: E05B47/00
Filed: 2007-07-10
Abstract: Disclosed is an electrical lock arrangement for use with domestic doors. The lock arrangement includes an electrically powered lock actuator, a power receiver (30) and a power transmitter (18). The electrically powered lock actuator is adapted for mounting in or on a door. The power receiver is adapted for mounting in or on the door in electrical connection with the lock actuator. The power transmitter is adapted for mounting adjacent the door and for transmitting power across an air gap to the power receiver. The receiver includes a first core, and the transmitter includes a second core, wherein the magnetic axes of the cores are parallel and spaced apart when the door is closed.
Patent NZ-575586-A (NZ)
Title: A neural response process
Inventor: LITHGROW BRIAN JOHN
IPC: A61B5/374
Filed: 2005-09-01
Abstract: A neural response system, includes electrodes for connecting to a person to obtain a neural response signal; an amplifier for receiving and producing a sampled form of said signal for processing; and an analysis module for processing the signal to generate a plot of time and frequency data for peaks in the 70 to 300 Hz range to display activity of components of a person's auditory system and mark any disorder such as Parkinson's disease and depression. The components can be Basal Ganglia components. (62) Divided Out of 553530
Patent NZ-577283-A (NZ)
Title: Use of a Myxoma virus that does not express functional M135R
Inventor: MCFADDEN GRANT
IPC: A61K35/768
Filed: 2006-03-06
Abstract: Disclosed is the use of an effective amount of Myxoma virus that does not express functional M135R for the manufacture of a medicament for inhibiting a cell that has a deficient innate anti-viral response, wherein the cell is chronically infected with a virus or is a human cancer cell. (62) Divided Out of 560840
Patent NZ-583510-A (NZ)
Title: Stem cells derived from the carotid body and uses thereof
Inventor: TOLEDO ARAL JUAN JOSE
IPC: A61K35/12
Filed: 2008-08-01
Abstract: Provided is a population of adult stem cells, isolated from the carotid body, wherein the cells are positive for the phenotypic marker GFAP (glial fibrillary protein and negative for the phenotypic markers TH (tyrosine hydroxylase) and nestin. The cells can be used to manufacture a medicament to treat neurodegenerative diseases including Alzheimers's and Parkinson's as well as various lesions in the nervous system.
Patent NZ-587057-A (NZ)
Title: Method of treating prostate cancer with the gnrh antagonist degarelix
Inventor: OLESEN TINE KOLD
IPC: A61K38/08
Filed: 2009-02-10
Abstract: Disclosed is the use of degarelix in the manufacture of a medicament for the reduction of cardiovascular and/or vascular side effects in a subject treated for prostate cancer.
Patent NZ-587105-A (NZ)
Title: Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
Inventor: CERAMI ANTHONY
IPC: C07K14/505
Filed: 2009-01-22
Abstract: Disclosed is an isolated tissue protective peptide comprising or consisting of the amino acid sequence UEQLERALNSS (SEQ ID NO 282). Further disclosed is a pharmaceutical composition comprising said peptide, and the use of said peptide in the manufacture of a medicament for use in treating a subject suffering from a disease associated with tissue damage, such as cancer, ischemia, trauma, toxic or inflammatory injuries. Also disclosed is a an isolated nucleic acid comprising a nucleotide sequence encoding said peptide, an expression vector comprising said nucleic acid, and an isolated host cell containing said expression vector.
Patent NZ-588698-A (NZ)
Title: Methods for treating disorders using nmda nr2b-subtype selective antagonist
Inventor: KEMP JOHN ALAN
IPC: A61K31/505
Filed: 2009-03-26
Abstract: Disclosed is the use of 5-(3-difluoromethyl-4-fluoro-phenyl)-3-(2-methyl-imidazol-1-yl-methyl)-pyridazine, represented by general formula (I), or pharmaceutically acceptable salts thereof, for the manufacture of a medicament formulated for administration to provide a total daily dose from about 2 to about 50 mg of the compound of formula (I) for the treatment, prevention or amelioration of cognitive impairment, a neurodegenerative disease, pain, depression, attention deficit hyperactivity disorder, or addiction.
Patent NZ-591132-A (NZ)
Title: Tray having shape to interlock with similar tray when trays overlapped
Inventor: TESINK TON
IPC: A47G23/06
Filed: 2009-03-04
Abstract: A combination of trays, in particular for catering purposes onboard aircraft, including at least a first tray (2) and a second tray (2'), a tray body (4, 4') of each tray defining a receiving surface (6, 6') for receiving thereon items to be carried by means of the tray. The tray body of the first tray includes interlocking means (14, 16) for releasably engaging interlocking means (14', 16') of the tray body of the second tray, so that when the trays are stored on a common surface and positioned such that the receiving surfaces of tray bodies overlap each other partially, the interlocking means of the trays interact such that when one of the trays is drawn in a drawing direction (12) along the common surface, the other tray is moved along in the drawing direction.
Patent NZ-595320-A (NZ)
Title: Electricity meter having compartments providing access to data communication components and battery
Inventor: NEHETE CHANDRASHEKHAR
IPC: G01R1/04
Filed: 2011-09-21
Abstract: Disclosed is compartmentalised energy meter (100). The meter (100) has an enclosure (102) having one or more service accessible compartments (104, 110). The service accessible compartments (104, 110) are operable for housing advanced metering infrastructure (AMI) components (106) and a replaceable battery (112). One or more compartment covers (108, 114) associated with the one or more service accessible compartments (104, 110) are also provided. The one or more compartment covers (108, 114) can be manipulated to access the one or more service accessible compartments (104, 110) and one or more replaceable AMI components (106) therein. The service accessible components comprise a battery compartment (110) for the replaceable battery (112), wherein the battery compartment (110) is separate from other service replaceable compartments.
Patent NZ-597920-A (NZ)
Title: Anhydrate of tiotropium bromide
Inventor: GORE VINAYAK GOVIND
IPC: A61K31/439
Filed: 2010-08-06
Abstract: The present disclosure relates to a novel form of anhydrous tiotropium bromide, processes for the preparation of anhydrous tiotropium bromide, pharmaceutical compositions comprising anhydrous tiotropium bromide and uses of the compositions. The disclosure further provides a process for the preparation of anhydrous tiotropium bromide, comprising the steps of: providing a solution of scopine di-(2-thienyl)glycolate and a ketone as the first organic solvent; adding a solution of methyl bromide in a second organic solvent to the mixture from step (a) or vice versa; isolating anhydrous tiotropium bromide from the mixture obtained in step (b); and drying the isolated anhydrous tiotropium bromide. The anhydrous tiotropium bromide may be used in the treatment of a respiratory disorder, such as asthma or COPD, wherein the COPD includes chronic bronchitis and emphysema, and my be administered from a dry powder inhaler (DPI), an aqueous nebulizer or a pressurized metered dosage inhaler (pMDI).
Patent NZ-598290-A (NZ)
Title: Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
Inventor: RINSCH CHRISTOPHER
IPC: C07D407/10
Filed: 2010-07-23
Abstract: The disclosure relate to isolated compounds, extracts and compositions thereof, and methods of using of the same, to treat neurodegenerative disorders and/or improve brain health. In certain embodiments, said compounds are pomegranate flavonoids. The flavanoids disclosed as medicaments include punicalin, pedunculagin, tellimagrandin, corilagin, granatine A, granatine B, terminalin, gallagyldilactone, punicalagin and compounds of formula I. Conditions which may be treated include: cognitive disorders, neurodegenerative disorders, amyloidosis-related conditions, amyotrophic lateral sclerosis (ALS), Huntington’s disease, Parkinson’s disease, Down syndrome, cognitive impairment, memory impairment, attention impairment, reaction time impairment, and learning impairment.
Patent NZ-599528-A (NZ)
Title: Percutaneous intravascular access to cardiac tissue
Inventor: KASSAB GHASSAN S
IPC: A61M25/01
Filed: 2007-06-29
Abstract: 599528 An engagement catheter (700) and system for engaging heart tissue is disclosed. The system includes an engagement catheter (700) having a proximal end (710), a distal end (720), and a lumen that extend between the proximal and distal ends. A vacuum port (770) is located at or near the proximal end (710) and is connected to the first lumen (730) which is in communication with a suction port (780) located at or near the distal end (720). The suction port (780) is configured to engage targeted tissue on an interior wall of a heart to form a reversible seal with the wall when a vacuum source is attached to the vacuum port (770). The system is capable of enlarging a pericardial space between the targeted tissue and a pericardial sac that surrounds the heart by retracting the targeted tissue away from the pericardial sac.
Patent NZ-603107-A (NZ)
Title: Non-hormonal steroid modulators of nf-kb for treatment of disease
Inventor: MCCALL JOHN M
IPC: A61K31/575
Filed: 2009-05-28
Abstract: 603107 Disclosed is the use of (10S,13S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one in the manufacture of a medicament for reducing the symptoms of a NF-kappaB disease selected from the group consisting of muscular dystrophy, traumatic brain injury, spinal cord injury, sepsis, rheumatic disease, cancer, atherosclerosis, type 1 diabetes, type 2 diabetes, leptospirosis renal disease, glaucoma, retinal disease, ageing, headache, pain, complex regional pain syndrome, cardiac hypertrophy, muscle wasting, catabolic disorders, obesity, foetal growth retardation, hypercholesterolemia, heart disease, chronic heart failure, ischemia/reperfusion, stroke, cerebral aneurysm, angina pectoris, pulmonary disease, cystic fibrosis, acid-induced lung injury, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, Jorgen’s syndrome, hyaline membrane disease, kidney disease, glomerular disease, alcoholic liver disease, gut diseases, peritoneal endometriosis, skin diseases, nasal sinusitis, mesothelioma, anhidrotic ectodermal dysplasia-ID, behcet’s disease, incontinentia pigmenti, tuberculosis, Cohn’s disease, colitis, ocular allergy, appendicitis, Paget’s disease, pancreatitis, periodontitis, endometriosis, inflammatory bowel disease, inflammatory lung disease, silica-induced diseases, sleep apnoea, AIDS, HIV-1, autoimmune diseases, antiphospholipid syndrome, lupus, lupus nephritis, familial Mediterranean fever, hereditary periodic fever syndrome, psychosocial stress diseases, neuropathological diseases, familial amyloidotic polyneuropathy, inflammatory neuropathy, Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s disease, cataracts, and hearing loss.
Patent NZ-608994-A (NZ)
Title: Ventilator
Inventor: TAREK ALFAKHRANY
IPC: F24F7/02
Filed: 2013-04-03
Abstract: A ventilator and ventilator system is disclosed. The ventilator (10) comprises a motor-driven rotor (12), and a stator (20) for mounting to the structure. The rotor is rotatably mounted to the stator. The ventilator also comprises an annular support framework (36) that extends up and away from an upper periphery of the stator. The annular support framework comprises a plurality of air passageways (34) arranged so as to enable the air to flow through the ventilator. The ventilator also comprises a cover (30) that is supported on the annular support framework. The cover can provide the ventilator with the ability to allow sunlight into an enclosed space within the structure.
Patent NZ-610034-A (NZ)
Title: Prevention of adverse effects caused by cd3 specific binding domains
Inventor: ZUGMAIER GERHARD
IPC: C07K16/28
Filed: 2011-10-27
Abstract: Discloses the use of a glucocorticoid (GC) in the preparation of a medicament for the amelioration, treatment or prophylaxis of a neurological adverse event in a patient caused by the administration of a CD3 binding domain.
Patent NZ-614825-A (NZ)
Title: Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system
Inventor: KETTSCHAU GEORG
IPC: C07C211/41
Filed: 2012-03-20
Abstract: Disclosed are compounds suitable for labelling by 18F and the corresponding 18F labelled compounds themselves, 18F-fluorinated analogues thereof and their use as reference standards, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by Positron Emission Tomography (PET). In one embodiment the compound is (1S,2S)-2-[18F]fluoro-N-[(1,1-2H2)prop-2-yn-1-yI]indan-1-amine. In another embodiment the compound is (3aS,8aR)-3-[(1,1-2H2)prop-2-yn-1-yl]-3,3a,8,8a-tetrahydroindeno[1,2d][1,2,3} oxathiazole 2,2-dioxide. In yet another embodiment the compound is potassium N-[(1 S,2S)-2-[18F]fluoroindan-1-yl]-N-[(1,1-2H2)prop-2-yn-1-yl]sulfamate.
Patent NZ-616512-A (NZ)
Title: Modulation of hepatitis b virus (hbv) expression
Inventor: MCCALEB MICHAEL L
IPC: C07H21/02
Filed: 2012-04-20
Abstract: Disclosed is a compound, comprising a single-stranded modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences disclosed, wherein at least one nucleoside of the single-stranded modified oligonucleotide comprises a modified sugar and the single-stranded modified oligonucleotide is at least 90% complementary to SEQ ID NO: 1, wherein the sequences are as defined in the specification. Also disclosed is the use of the compound for treating a HBV-related disease, disorder or condition
Patent NZ-630702-A (NZ)
Title: Patient interface and method for making same
Inventor: BARLOW ADAM FRANCIS
IPC: F16L11/00
Filed: 2014-01-16
Abstract: A cushion or padding member for supply of oxygen or air to a patient, which includes a retaining structure (3240) and a seal-forming structure (3100) permanently connected to the retaining structure. The seal forming structure seals below the bridge of the nose has a single opening that supplies air to both nostrils or nares of a patient. Alternative embodiments are either: configured to increase sealing force when the air pressure is increased; or include a recessed portion for receiving the tip of a nose.
Patent NZ-700280-A (NZ)
Title: Methods for producing new packaging designs based on photoprotective materials
Inventor: JERNAKOFF PETER
IPC: G01N33/15
Filed: 2013-04-25
Abstract: This invention provides methods for quantification of photoprotective performance of packaging concepts in an accelerated timeframe. In certain embodiments, the apparatus and methods can be used to generate models for the prediction of photoprotective performance values of untested materials based upon some other known qualitative or quantitative property. The models may be used to identify a packaging material for use in a package design. In certain embodiments the package design provides targeted photoprotection appropriate for the package contents, such as a photosensitive nutrient.
Patent NZ-702169-A (NZ)
Title: The use of heat shock protein 90 (hsp90) modulators for the treatment of metabolic syndrome
Inventor: NARAIN NIVEN RAJIN
IPC: A61K48/00
Filed: 2013-05-24
Abstract: The invention provides HSP90 modulators for use in the manufacture of a medicament for treating a metabolic syndrome in a subject with metabolic syndrome. The subject with metabolic syndrome exhibits three or more of the following signs: a) blood pressure equal to or higher than 130/85 mmHg; b) fasting blood glucose equal to or higher than 100 mg/dL; c) large waist circumference wherein a large waist circumference is 40 inches or more for men and 35 inches or more for women; d) low HDL cholesterol wherein low LDH cholesterol is under 40 mg/dL for men and under 50 mg/dL; and e) triglycerides equal to or higher than 150 mg/dL.
Patent NZ-711400-A (NZ)
Title: Temperature shift for high yield expression of polypeptides in yeast and other transformed cells
Inventor: MCNEILL PATRICIA DIANNE
IPC: C12N1/19
Filed: 2014-03-17
Abstract: Methods for producing heterologous proteins are disclosed. In particular, the present disclosure provides improved methods of producing desired proteins, including multi-subunit proteins such as antibodies, with a higher yield and improved purity. The transformed cells used are a methylotrophic yeast of the genus Pichia, more specifically Pichia pastoris. The method further involves culturing the cells at two different temperatures, the first being between 27.5-28.5 degrees celsius and the second being between 30-31 degrees celsius. Additionally, the promoter used to control expression of the desired antibody is not temperature inducible.
Patent NZ-711451-A (NZ)
Title: Anti-c5 antibodies having improved pharmacokinetics
Inventor: TAMBURINI PAUL P
IPC: C07K16/36
Filed: 2014-09-11
Abstract: Disclosed is a nucleic acid encoding a heavy chain polypeptide and a light chain polypeptide of an antibody, wherein the heavy chain polypeptide comprises the amino acid sequence depicted in SEQ ID NO: 14 and the light chain polypeptide comprises the amino acid sequence depicted in SEQ ID NO: 11, wherein the sequences are as defined in the complete specification. Also disclosed is a nucleic acid encoding complementarity determining regions (CDRs) of heavy and light chain variable regions of an antibody, or antigen-binding fragment thereof, comprising the amino acid sequences depicted in SEQ ID NOs: 12 and 8, respectively.